We read with interest the article by Khoja et al. [1], in which the authors reviewed systematically tumor-and class-specific patterns of immune-related adverse events of immune-checkpoint inhibitors. Their analysis revealed distinct immune related adverse events (irAE) profiles for anti-CTLA4 and anti-PD1/PDL1 antibodies, as well as different tumor histologies.
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The authors correctly point out various factors which could contribute to these distinct irAE profiles in different tumor types, such as differences in the immune cell infiltration and neoantigen formation, and suggest that differences in patient characteristics, such as pharmacologic responses, microbiome and comorbidities may as well play a role in this context. However, they do not mention a further important determinant of immune responses: a patient's sex.
Sex is a biological variable that affects immune responses to both self and foreign antigens across various species [2] . Different mechanisms could contribute to the overall stronger immune responses found in women as compared with men, including the localization of immune related genes and miRNA implicated in their regulation on the X chromosome and the control of immune cell differentiation and function by sex hormones [2] . The incidence of autoimmune diseases is significantly higher in women, and alterations of sex hormone levels in pregnancy or menopause are known to affect their outcome [2] . Thus, types, frequency and/or severity of irAEs may-in addition to the factors discussed by Khoja et al. -as well be influenced by sex. While the sexual dimorphism in drug response, with differences in metabolism due to variances in body size, distribution volumes, sex hormone levels and activity of enzymes is well known in cardiovascular medicine [3] , its potential clinical relevance in oncology is largely unknown and ignored.
Generally, in oncology, the balance between the efficacy and toxicity of a drug might not be the same in men and in women. To understand this balance is a major challenge for drug development. Especially for checkpoint inhibitors, and in view of a positive correlation between the occurrence of irAEs and response rates, the question whether sex differences are present is of particular importance [4] . There is emerging evidence from animal experiments showing that PD-1 expression is sex-dependent and modulated by estrogens. Moreover, data from preclinical melanoma models and clinical trials suggests that female sex is a predictor of poor response to anti-PD-1 therapy [5] . To the best of our knowledge, data on the impact of sex on tumor response, as well as a possible correlation with irAEs for different types of checkpoint inhibitors and tumor types have not been reported and are urgently required. Inadequate inclusion of women in clinical trials in many disciplines, including oncology, despite the recommendations of important regulatory bodies such as the Food and Drug Administration and the National Institute of Health [6] is only one reason why obtaining this kind of data is challenging.
In our view, sex is a fundamental biological variable, affecting a vast range of cellular functions in different organs, with impact in both physiological and pathological conditions, which deserves more attention in oncology. A 74-year-old patient (patient 1) and a 64-year-old patient (patient 2) were diagnosed with monomelic endemic KS. The first patient initially presented with cutaneous involvement and subsequent muscular, bone and lymph node extension that were successively treated with radiation therapy, bleomycine, vincristine, anthracyclines and paclitaxel; the second patient had bone and lymph node extension, previously treated with radiation therapy, and anthracyclines. Little and non-durable benefit were observed in both cases. In 2016, severe disease progression was diagnosed, requiring the daily use of opioids and resulting in severe walking disability (patients 1 and 2) and complicated with Staphylococcus aureus than Proteus mirabilis osteomyelitis of the right ankle (patient 2). Both refused amputation. Considering the well-known immunomodulation of KS, the major efficacy of anti-PD-1 antibody in Merkel cell carcinoma [1] , another virusassociated immunomodulated tumor, and since no other standard therapy was available, they received nivolumab 3 mg/kg every 2 weeks. Twelve weeks after starting nivolumab (six cycles), 18F-2-fluoro-2-deoxy-D-glucose positon emission tomography (FDG-PET) showed significant partial response for both patients. The walking function of patients 1 and 2 improved and opioids were stopped. After 24 weeks (12 cycles of nivolumab), the clinical benefit was confirmed (Figure 1 ). Last tumor evaluation (FDG-PET and magnetic resonance imaging) showed stable partial response for both patients except for one preexisting nodule on the right foot, which required concomitant radiotherapy (patient 1). In patient 2, the P. mirabilis osteomyelitis was treated with ceftriaxone for 6 months and was stable. Tumor biopsies carried out at baseline were retrospectively tested for PD-L1 expression using immunohistochemistry. PD-L1 was positive in patient 1 (1%-5% of tumor cells) and negative in patient 2 (<1%). Clinical tolerance was good; a biological adrenal insufficiency revealed by hyponatremia associated with a low cortisol and a normal adrenocorticotropic hormon (ACTH) level was diagnosed after 16 weeks (patient 1), requiring hormone-replacement therapy.
Classic and endemic KS is a cutaneous lymphangioproliferation associated with human herpes virus 8, occurring in patients without HIV infection nor iatrogenic immunosuppression. Treatment is based on chemotherapy, mainly anthracycline or paclitaxel resulting in 30%-60% of transient responses, or interferon therapy which is poorly tolerated [2, 3] . Immunotherapy has proven to be effective in several solid cancers including Merkel cell carcinoma [1] . Moreover, recent data demonstrated that PD-1 is expressed on tumor cells or in tumor microenvironment in KS [4] and that it inhibits NK cells functions, thus promoting tumor progression [5] .
These two cases suggest that anti-PD-1 blockade with nivolumab could be effective in the treatment of refractory KS. Prospective clinical studies are warranted to confirm this result. Letters to the editor 
